Research programme: methionine aminopeptidase inhibitors - Zafgen

Drug Profile

Research programme: methionine aminopeptidase inhibitors - Zafgen

Alternative Names: ZGN 839; ZGN-201

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator Zafgen
  • Class Small molecules
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Obesity
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 10 Mar 2017 methionine aminopeptidase inhibitors is still in Preclinical development for Obesity in USA (Zafgen pipeline, April 2017)
  • 10 Mar 2017 Preclinical trials in Inflammation in USA (PO) before March 2017 (Zafgen pipeline, April 2017)
  • 01 Mar 2017 Zafgen has patent protection for MetAP2 inhibitors in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top